Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN) (Abstract)

The LDN 2021 Conference Recordings Now Available with up to 29 CME Credits [More Details]

Medical Professionals Become an LDN Specialist [More Details]

Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN)

J Neuroimmune Pharmacol
June 2013
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661907/

Complex Regional Pain Syndrome (CRPS) is a neuropathic pain syndrome, which involves glial activation and central sensitization in the central nervous system. Here, we describe positive outcomes of two CRPS patients, after they were treated with low-dose naltrexone (a glial attenuator), in combination with other CRPS therapies. Prominent CRPS symptoms remitted in these two patients, including dystonic spasms and fixed dystonia (respectively), following treatment with low-dose naltrexone (LDN). LDN, which is known to antagonize the Toll-like Receptor 4 pathway and attenuate activated microglia, was utilized in these patients after conventional CRPS pharmacotherapy failed to suppress their recalcitrant CRPS symptoms.

Keywords: Chronic pain, Complex regional pain syndrome, CRPS, Reflex sympathetic dystrophy, RSD, Neuropathic pain, Naltrexone, Fixed dystonia, Allodynia, Vasomotor, Ulceration, Dystonic spasms, Conversion disorder, Functional movement disorder, LDN